Gilead Sciences (GILD) Capital Expenditures (2009 - 2026)

Gilead Sciences (GILD) has reported Capital Expenditures for 18 consecutive years, with $117.0 million the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $117.0 million, up 12.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $576.0 million (up 10.34% YoY), and the FY2025 annual result was $563.0 million, up 7.65% from the prior year.
• Capital Expenditures was $117.0 million for Q1 2026 at Gilead Sciences, down from $205.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $247.0 million in Q1 2022 and troughed at $104.0 million in Q1 2025.
• Average Capital Expenditures over 5 years is $148.0 million, with a median of $141.0 million recorded in 2024.
• Year-over-year, Capital Expenditures surged 49.7% in 2022 and sank 55.87% in 2023.
• Over 5 years, Capital Expenditures stood at $181.0 million in 2022, then advanced by 18.78% to $215.0 million in 2023, then slumped by 31.63% to $147.0 million in 2024, then soared by 39.46% to $205.0 million in 2025, then slumped by 42.93% to $117.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $117.0 million in Q1 2026, $205.0 million in Q4 2025, and $147.0 million in Q3 2025.